Disease relevance of ADAM29

• The LPL/ADAM29 expression ratio is a novel prognosis indicator in chronic lymphocytic leukemia [1].

High impact information on ADAM29

• Overall, quantification of LPL and ADAM29 gene expression is a strong prognostic indicator in CLL, providing better prognostic assessment than ZAP-70 in advanced stages of the disease [1].
• LPL and ADAM29 gene expression could also be determined by a simple competitive multiplex reverse transcription PCR assay [1].
• Molecular cloning and mapping of a novel ADAM gene (ADAM29) to human chromosome 4 [2].
• Northern blot analysis revealed that the mRNA of ADAM29 is highly expressed in the testis [2].
• ADAM29 and ADAM30 map to human chromosome 4q34 and 1p11-13, respectively [3].

Other interactions of ADAM29

• We have isolated cDNAs encoding two novel members of this family, ADAM29 and ADAM30 which show testis-specific expression [3].
• Multivariate Cox regression analysis identified LPL, ADAM29 and CD38 as independent prognostic markers [4].
• IGVH mutational status, ZAP-70, and the LPL and ADAM29 mRNA ratios (L/A ratio) were predictive of event-free survival for the whole cohort and for patients with stage A disease [1].

Analytical, diagnostic and therapeutic context of ADAM29

• By radiation hybrid panel mapping, the ADAM29 gene was assigned to human chromosome 4q34.2-qter [2].

References